Guerbet announces US FDA approval of Elucirem (gadopiclenol)

Guerbet

21 September 2022 - FDA approval of Elucirem was granted after priority review, a designation assigned to applications for drugs that provide significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions compared to available therapies.

Guerbet announced today that the US FDA after priority review, approved Elucirem (gadopiclenol), a new macrocyclic GBCA for use in contrast-enhanced magnetic resonance imaging.

Read Guerbet press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , US , Diagnostic agent